TGRX-678 Pharmacokinetic Mass Balance

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

August 17, 2025

Study Completion Date

August 25, 2025

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

[14C]TGRX-678

Healthy subjects will be given TGRX-678 240 mg orally on day 1.

Trial Locations (1)

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY